1. Home
  2. HRMY vs ADUS Comparison

HRMY vs ADUS Comparison

Compare HRMY & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$31.05

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$98.27

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
ADUS
Founded
2017
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
HRMY
ADUS
Price
$31.05
$98.27
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$44.11
$133.78
AVG Volume (30 Days)
793.3K
232.9K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
23.40
EPS
2.71
1.36
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.75
$9.17
Revenue Next Year
$12.88
$4.70
P/E Ratio
$12.04
$71.12
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$90.89
52 Week High
$40.87
$124.44

Technical Indicators

Market Signals
Indicator
HRMY
ADUS
Relative Strength Index (RSI) 51.87 52.42
Support Level $25.92 $91.33
Resistance Level $30.96 $120.09
Average True Range (ATR) 1.47 3.25
MACD 0.07 0.53
Stochastic Oscillator 35.36 57.48

Price Performance

Historical Comparison
HRMY
ADUS

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.

Share on Social Networks: